Trans-apical Aortic Valve Implantation for Quadricuspid Aortic Valve With Aortic Regurgitation Using J-valve System: A Case Report

Chaodi Luo
X'i'an Jiaotong University Medical College First Affiliated Hospital

Yi Jiang
X'i'an Jiaotong University Medical College First Affiliated Hospital

Yang Yan
X'i'an Jiaotong University Medical College First Affiliated Hospital

Dan Han (handan1789@163.com)
The First Affiliated Hospital of X'i'an Jiaotong University

Case report

Keywords: Quadricuspid aortic valve, Transapical aortic valve implantation, Case report

DOI: https://doi.org/10.21203/rs.3.rs-469054/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Quadricuspid aortic valve (QAV) is a rare congenital heart defect usually accompanied with different hemodynamic abnormalities. Due to the rarity of QAV, treatment and prognosis of QAV patients with aortic regurgitation still remain challenging. We here present the first case of a patient with severe QAV regurgitation who underwent successful treatment and performed favorable prognosis with transapical aortic valve implantation (TAVI) using J-Valve system.

Case presentation: A 62-year-old man experienced intermittent palpitation, shortness of breath and chest pain. Echocardiography revealed congenital QAV with massive aortic regurgitation and mild aortic stenosis, left ventricular enlargement. Aortic valve replacement was successfully performed with TAVI using J-Valve system. The postoperation and follow-up was uneventful.

Conclusion: Transapical aortic valve implantation (TAVI) using J-Valve system has emerged as a new high success rate method for treatment of high-risk patients with simple non-calcified aortic valve insufficiency.

Introduction

Quadricuspid aortic valve (QAV) is a rare congenital heart defect with an estimated incidence between 0.003% and 0.013%. Patients with QAV usually present with hemodynamic abnormalities, most commonly aortic regurgitation.(1) Diagnosis of QAV based on echocardiography is not difficult, however, the repaired prosthesis durability and long-term outcomes of such non-tricuspid aortic valves remain uncertain.(2) Surgical aortic replacement has long been the first choice for aortic regurgitation, however, it may increase the complications and mortalities for high-risk patients.(3) On the other hand, for patients with simple non-calcified aortic valve insufficiency, many transcatheter aortic valve products are not reliable enough to anchor, and postoperative perivalvular leakage or valve displacement is easy to occur, which limit their applicability.(4) Transapical aortic valve implantation (TAVI) using J-Valve system has emerged as a new method for treatment of high-risk patients with simple non-calcified aortic valve insufficiency.(5) Due to the rarity of QAV, only a few cases of stenosed QAVs treated with transcatheter aortic valve implantation have been reported.(6, 7) We here present the first case of a patient with severe QAV regurgitation who underwent successful treatment and performed favorable prognosis with TAVI using J-Valve system.

Case Presentation

A 62-year-old man was admitted to our department with a history of hypertension, intermittent palpitation, shortness of breath and chest pain for 10 years. Echocardiography revealed congenital QAV (Supplemental video 1) with massive aortic regurgitation and mild aortic stenosis, left ventricular enlargement (Fig. 1). Ventricular function was normal with the left ventricular ejection fraction of 59%. Cardiac computed tomography (CCT) revealed type A QAV without significant valvular thickening or
calcification, average aortic annulus diameter was 25.9 mm, ascending aortic diameter was 31.8 mm, sinotubular junction was 28.8 mm, average left ventricular outflow tract diameter was 28.2 mm. The patient had relatively low coronary ostial height with the left coronary artery arising only 11.5 mm from the valve annulus, and the right coronary ostial height was 14.7 mm (Supplemental Fig. 1). As such, the patient was deemed not to be a suitable candidate for conventional surgical repair (EuroSCORE = 2) or commercially available transcatheter valves. Our heart team evaluated and recommended TAVI using J-Valve system. The informed consent was obtained from the patient. Hospital ethics committee approval was also granted.

Under general anaesthesia, the patient underwent successful implantation of a 27-mm J-Valve via transapical access in a hybrid operating room. At the beginning, a 6F pigtail catheter was inserted into the aortic sinus via the left femoral artery and a temporary pacemaker was implanted to the right ventricular apex via the left femoral vein (Supplemental video 2). Aortic root angiography and transesophageal echocardiography (TEE) were utilized for evaluation of the valve pathology (Fig. 2) and apical position. The C-arm position was adjusted according to the previous CCT data so that the three aortic sinuses are simultaneously displayed and located in the same plane. Next, a 4-cm tiny incision was made at the fifth costal margin to expose the pericardium. The apical puncture was performed, TEE and fluoroscopy showed that super-stiff guidewire was placed in position and did not affect mitral valve tendinous cord (Supplemental video 3). According to preoperative assessment, a 27-mm J-Valve (Jie-cheng Medical Technology, Suzhou, China) was crimped into the delivery system and transported into a supra-annular position following fluoroscopic guidance. With the assistance of pigtail catheter under fluoroscopy and TEE, the three “U-shape” graspers were carefully folded as three “long elliptical shape” in favor of positioning and then totally released into the left-, right- and non-coronary sinuses to clamp the native leaflets (Supplemental video 4). The correct position was confirmed by fluoroscopy and TEE, the valve was then delivered into the annular plan guided by the graspers and released with rapid ventricular pacing at 120 bpm (Supplemental video 5). After withdrawing the delivery system, TEE and aortic root angiography showed no aortic regurgitation as well as no paravalvular leak with patent coronaries and good valve stent position, and the artificial aortic valve worked well (Supplemental video 6,7,8). There was no intraoperative or perioperative complication. The patient did well postoperatively and discharged home in good clinical condition after 10 days. Six months later, our patient was followed up at the outpatient, he made a successful recovery, echocardiography revealed that the artificial aortic valve functioned normally, the left ventricular diameter and ventricular function were normal with the left ventricular ejection fraction of 64% (Fig. 3).

Discussion

QAV accompanied by different hemodynamic abnormalities is usually treated with surgical valve repair or valve replacement with a synthetic valve. However, surgery may increase the incidence of valve thrombosis, prosthetic valve endocarditis, reduced valve durability, kidney injury, and bleeding complications.(3) Transcatheter valve implantation is now increasingly applied in clinical practice, which includes valve-in-valve treatment for failing bio-prostheses, low-risk patients, native pure aortic
regurgitation, and for treatment of congenital valve disease such as bicuspid aortic valves with complex anatomical characteristics. Nevertheless, due to the scarcity of QAV, the durability of prosthetic valve and long-term outcomes remain uncertain. To date, only a few cases of stenosed QAV treated successfully with transcatheter valve implantation have been reported. Unlike aortic stenosis, transcatheter valve implantation is not yet recommended in guidelines for treating pure aortic regurgitation. Some previous off-label clinical experiences showed that the rate of all-cause mortality using the first-generation transcatheter devices in treating pure aortic regurgitation at 30 days was up to 30%, as well as the high incidence of postoperative complications encompassing perivalvular leakage, residual aortic regurgitation, valve-in-valve procedures, fatal bleeding, major vascular damage, permanent pacemaker implantation, acute kidney injury, and stroke. Therefore, treatment and prognosis of QAV patients with aortic regurgitation are still challenging.

J-Valve with three “U-shape” graspers is a second-generation self-expandable device which has been approved for treating both aortic stenosis and aortic regurgitation in China. The unique structures of J-Valve system are effective for positioning, anchoring and protecting coronary arteries: (1) the three U-shape graspers are conductive to anchor the leaflets, which decreases the risk of perivalvular leakage and valve displacement; (2) the short path from the apex to the aortic annulus is helpful for adjusting the coaxiality and reducing major vascular damage; (3) because the fixation of J-Valve does not need a robust radial support force, it can be released at a lower level to reduce the rate of conduction block; (4) the low profile and bare metal area are designed for graspers to avoid coronary occlusion, especially for further coronary recanalization after primary valve replacement.

Liu et al. reported that a success rate of 97.7% and a mortality rate of 4.7% were observed in patients with pure aortic regurgitation treated by J-Valve. The rate of permanent pacemaker implantation was 4.7%, 2.3% patients suffered stroke, and the treatment for failing prostheses rate was 7.0%. During 1-year follow-up, only one patient had mild perivalvular leakage. Xue et al. discovered that the success rate of J-Valve implantation was 91.3%, and the mortality was 4.3%. No cases underwent permanent pacemaker implantation and only one patient suffered mild stroke. No paravalvular leakage was observed during the follow-up. To sum up, the new-generation devices such as J-Valve had a higher device success and a significant reduction in postoperative complications compared to the old-generation.

It is worth noting that the angles among the adjacent graspers are 120°, whereas the angles of adjacent QAV leaflets are 90°. Considering the mismatching between the graspers and the leaflets, we carefully rotated the graspers during the procedure to ensure them capturing the leaflets instead of translocation. Second, valve positioning was fluoroscopically challenging. We folded the three “U-shape” graspers as three “long elliptical shape” under fluoroscopy, which was very helpful for positioning. Third, the position of the left main coronary ostia was relatively low, which needed to be prudently considered in case of coronary occlusion.

**Conclusion**
In conclusion, our case adds to the body of evidence supporting the fact that TAVI using J-Valve in treating QAV patient with severe aortic regurgitation is feasible and showed favorable prognosis. Valve positioning and low left main coronary ostia should be prudently considered during the procedure.

**Abbreviations**

QAV
Quadricuspid aortic valve;
TAVI
transapical aortic valve implantation;
CCT
Cardiac computed tomography;
TEE
Transesophageal echocardiography.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by Institutional Review Board of The First Hospital of Xi’an Jiaotong University.

**Consent for publication**

Written informed consent for publication was obtained from the study individual. Copy of the consent form is available for review by the Editor of this journal.

**Availability of data and materials**

The datasets of the current study are available from the corresponding author upon reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This study was supported by the Basic Research Foundation of the First Affiliated Hospital of Xi’an Jiaotong University, China (No. 2020QN-30).

**Authors’ contributions**

Dr. Chaodi Luo and Dr. Dan Han: collected the primary data and drafted the initial manuscript. Dr. Yang Yan: diagnosed the case and instructed the patient’s treatment. Dr. Yi Jiang: assisted with the treatment
of the patient. All authors contributed to discussions and critically appraised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Acknowledgements

We appreciate the patient for his understanding and cooperation. We thank Dr. Fengwei Guo and Dr. Yongxin Li for their wonderful surgical procedures and interpretation of the pictures and videos.

Author details

1Department of Cardiology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, PR China

2Department of Cardiovascular Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, PR China

References

1. Yuan SM. Quadricuspid Aortic Valve: A Comprehensive Review. Brazilian journal of cardiovascular surgery. 2016;31(6):454-60.

2. Mastrobuoni S, Aphram G, Tamer S, Navarra E, De Kerchove L, El Khoury G. Quadricuspid aortic valve repair. Annals of cardiothoracic surgery. 2019;8(3):433-5.

3. Lorca R, Álvarez-Cabo R, Calvo J, de la Hera JM. Quadricuspid aortic valve surgical repair. The Journal of thoracic and cardiovascular surgery. 2018;155(3):940-1.

4. Howard C, Jullian L, Joshi M, Noshirwani A, Bashir M, Harky A. TAVI and the future of aortic valve replacement. 2019;34(12):1577-90.

5. Ye J, Lee AJ, Blanke P, Webb J. The first transapical transcatheter aortic valve-in-valve implantation using the J-valve system into a failed biophysio aortic prosthesis in a patient with high risk of coronary obstruction. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2018;92(6):1209-14.

6. Benkemoun H, Bramlage P. A four-leaf clover: A case report of quadricuspid aortic valve stenosis. 2020;35(5):1125-8.

7. Ibrahim M, Wattanakit K, Barzallo M, Mungee S. Quadricuspid Aortic Valve Stenosis: Expanding Our Experience in Transcatheter Aortic Valve Implantation. The Journal of invasive cardiology. 2018;30(3):E27.

8. Puri R, lung B, Cohen DJ, Rodés-Cabau J. TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. European heart journal. 2016;37(28):2217-25.

9. Franzone A, Piccolo R, Siontis GC, Lanz J, Stortecky S, Praz F, et al. Transcatheter Aortic Valve Replacement for the Treatment of Pure Native Aortic Valve Regurgitation: A Systematic Review. JACC Cardiovascular interventions. 2016;9(22):2308-17.
10. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, et al. Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. Journal of the American College of Cardiology. 2017;70(22):2752-63.

11. Xue Y, Zhou Q, Li S, Li J, Mu D, Luo X, et al. Trans-apical transcatheter valve replacement using J-Valve for aortic valve diseases. The Annals of thoracic surgery. 2020.

12. Liu H, Yang Y, Wang W, Zhu D, Wei L, Guo K, et al. Transapical transcatheter aortic valve replacement for aortic regurgitation with a second-generation heart valve. The Journal of thoracic and cardiovascular surgery. 2018;156(1):106-16.

Figures

Figure 1

Echocardiography showed left ventricular enlargement (Panel A, red star shows dilated ventricle), quadricuspid aortic valve (Panel B, red arrow shows four aortic valves, which have been marked
numerically), mild aortic stenosis (Panel C, red arrow indicates the hole formed by aortic insufficiency, the area of which is about 0.124cm²) and massive aortic regurgitation (Panel D) of the QAV patient.

Figure 2

Long axial section of left ventricle of TEE showed massive aortic regurgitation before the procedure.
Figure 3

Echocardiography revealed that the artificial aortic valve worked well (red arrow).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- CAREchecklist.pdf
- SupplFigure1.tif
- SupplV1.mp4
- SupplV2.mp4
- SupplV3.mp4
- SupplV4.mp4
- SupplV5.mp4
- SupplV6.mp4
